JBIO Projected Dividend Yield

Jade Biosciences Inc. ( NASDAQ : JBIO )

Aerovate Therapeutics Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, its dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH), a devastating disease impacting approximately 70,000 people in the U.S. and Europe. Oral imatinib also demonstrated statistically significant improvement on the primary endpoint, six-minute walk distance, and multiple secondary hemodynamic endpoints in PAH patients.

21 YEAR PERFORMANCE RESULTS